Introduction
============

Some of the most prevalent and concerning effects of cancer treatment are chemotherapy-induced nausea and vomiting (CINV) ([@B12]; [@B20]). CINV leads to reduced chemotherapy adherence rates, deteriorated of function and quality of life (QOL), and aggravated anxiety and depression ([@B27]; [@B8]). Therefore, circumvention of CINV is a critical element of supportive care in cancer.

In recent years, the incidence of CINV has been decreasing through the improvement of antiemetic agents ([@B33]; [@B4]; [@B11]) and refinements of antiemetic guidelines by the American Society of Clinical Oncology (ASCO) ([@B9]), Multinational Association of Supportive Care in Cancer/European Society of Medical Oncology (MASCC/ESMO) ([@B14]), National Comprehensive Cancer Network (NCCN) ([@B21]), and Japan Society of Clinical Oncology (JSCO) ([@B13]). However, CINV still occurs in approximately half of patients who receive chemotherapy for cancer ([@B2]), and additional CINV prevention methods are required.

The emetogenicity of anti-cancer agents has been categorized according to their risk levels in the guidelines set by ASCO ([@B9]), MASCC/ESMO ([@B14]), NCCN ([@B21]), and JSCO ([@B13]). A chemotherapy regimen that is associated with emesis in ≥90% of patients is considered to have high emetic risk (highly emetogenic chemotherapy, HEC), regimens that cause emesis in 30--90% of patients are considered to have a moderate emetic risk (moderately emetogenic chemotherapy, MEC), those causing emesis in 10--30% of patients have a low emetic risk, and those causing emesis in less than 10% of patients have a minimum emetic risk. In all clinical guidelines, cisplatin (CDDP) is classified as HEC and carboplatin (CBDCA) as MEC. With these regimens, the patients are at risk of developing CINV for up to 120 h after receiving chemotherapy; this 120-h watch period for CINV incorporates an acute phase (0--24 h), delayed phase (\>24--120 h), and overall phase (0--120 h).

The treatments recommended by the international antiemetic guidelines of ASCO ([@B9]), MASCC/ESMO ([@B14]), NCCN ([@B21]), and JSCO ([@B13]) for the prevention of CINV that is associated with HEC are a neurokinin 1 receptor antagonist (NK-1-RA), a serotonin receptor antagonist (5HT~3~-RA), and dexamethasone (DEX); those for MEC include 5HT~3~-RA, DEX, and (optionally) NK-1-RA.

Herbal medicines, which were systemically popularized in Japan in the 16th century, have a wide range of indications aimed at maintaining QOL in patients rather than curing them ([@B18]). Herbal medicines are thus intended to boost the body's own healing power (i.e., immune system) and help restore its natural balance. Rikkunshito, an herbal medicine, has been shown to improve upper gastrointestinal symptoms and anorexia ([@B32]; [@B23]; [@B3]; [@B31]); therefore, we hypothesized that this herbal medicine can reduce CINV. Rikkunshito was approved in Japan only as a fixed dose of 7.5 g (2.5 g three times a day).

To the best of our knowledge, there are no prospective studies on the efficacy of herbal medicines in preventing CINV. Herein, we describe the results of two separate prospective, randomized, phase II parallel design studies that evaluated the efficacy and safety of rikkunshito in the prevention of CINV in patients with lung cancer receiving CDDP-based HEC (HOT1402) and CBDCA-based MEC (HOT1403).

Materials and Methods {#s1}
=====================

This study comprised two separate prospective, randomized phase II Hokkaido Lung Cancer Study Group Trial (HOT) investigations that were conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines ([@B34]), and CONSORT guidelines. The protocol was approved by the institutional review boards of all participating institutions, and all patients provided written informed consent before treatment. This study was registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000014239 (HOT1402) and UMIN000014240 (HOT1403).

Patient Eligibility
-------------------

Eligible patients met the following criteria: histologic or cytologic confirmation of lung cancer; age ≥20 years; an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0--2; treatment with CDDP-based HEC (HOT1402) or CBDCA-based MEC (HOT1403); adequate bone marrow function (leukocyte count ≥3,000/mm^3^, neutrophil count ≥1,500/mm^3^, platelet count ≥100,000/mm^3^, and hemoglobin content ≥9.0 g/dL); adequate function in other organs (total bilirubin concentration ≤1.5 mg/dL, aspartate transaminase and alanine transaminase levels ≤100 IU/L, and creatinine clearance ≥60 mL/min \[HEC\] or ≥50 mL/min \[MEC\]); P~a~O~2~ ≥60 Torr, or S~p~O~2~ ≥92%; and a life expectancy of 2 months or more. Patients who previously used rikkunshito or had active infectious diseases, serious medical complications (e.g., active peptic ulcer, heart disease, diabetes mellitus, cerebrovascular disease, neuropsychiatric disorder), had symptomatic brain metastasis, were lactating or pregnant, or had active concomitant malignancies were ineligible for the study.

Treatment Plan
--------------

Eligible patients were randomized in a 1:1 ratio using a minimization method and were assigned to receive either (1) standard antiemetic therapy in accordance with the ASCO ([@B9]), NCCN ([@B14]), MASCC/ESMO ([@B21]), or JSCO ([@B13]) guidelines at the investigators' discretion (the S group) or (2) standard antiemetic therapy plus 2.5 g of oral rikkunshito three times a day on days 1--7 (the R group). The stratification factors included sex, habitual alcohol intake (yes or no), and palonosetron use (yes or no) in the HEC study, and sex, habitual alcohol intake (yes or no), and NK-1-RA use (yes or no) in the MEC study.

Assessment
----------

The efficacy and safety of the antiemetic therapy were evaluated during the 7 days following the administration of the HEC or MEC in the first cycle. The patients recorded episodes of emesis, nausea ratings, and rescue medications taken during the first 120 h, as well as any impairment of eating habits during the first 7 days post-chemotherapy, in a diary. Patients assessed their nausea with a 100-mm horizontal visual analog scale (VAS); scores of ≤5 and ≤25 mm on the VAS scale indicated no nausea or no significant nausea, respectively. The patients also recorded the ratio of dietary intake with a 100-mm horizontal VAS. Adverse events related to the antiemetic treatment were surveyed by the investigators according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Objectives
----------

The primary endpoint was the complete response (CR; i.e., no emesis and no rescue medication) rate in the overall post-chemotherapy phase. The secondary endpoints were (1) the CR rate in the acute and delayed phases; (2) complete protection (CP; i.e., no emesis, no significant nausea, and no rescue medication) rate in the acute, delayed, and overall phases; (3) total control (TC; i.e., no emesis, no nausea, and no rescue medication) rate in the acute, delayed, and overall phases; (4) dietary intake during the 7 days post-chemotherapy; and (5) safety.

Statistical Analysis
--------------------

These two prospective, randomized phase II studies were designed to assess antiemetic efficacy with regard to the CR rate during the overall phase. The primary endpoint was CR rate in the overall phase among all per-protocol patients. The sample size was determined according to a one-arm binomial design devised by the Southwest Oncology Group. In the HEC study, we estimated the patient accrual number to be 27 assuming that a CR of 80% in eligible patients would indicate potential usefulness while a CR of 55% would be the lower limit of interest ([@B10]; [@B24]; [@B17]; [@B29]), with α = 0.05 and β = 0.20. To allow for patient dropouts, we aimed for the enrollment of 58 patients in the HEC study. In the MEC study, the estimated accrual number was 29 patients, assuming that a CR of 75% in eligible patients would indicate potential usefulness while a CR of 50% would be the lower limit of interest ([@B7]; [@B1]; [@B25]), with α = 0.05 and β = 0.20. We aimed to enroll 62 patients in the MEC study to allow for dropouts. Categorical variables were analyzed by using the χ^2^ or Fisher's exact tests. All *P*-values are 2-sided; a *P*-value of 0.05 indicated statistical significance. Statistical analyses were performed by using Excel 2011 (Microsoft) with the add-in software Statcel 4 (OMS Publishing Inc., Saitama, Japan).

Results
=======

Patient Characteristics
-----------------------

Between July 2014 and January 2016, 58 patients who received HEC (29 each in the S and R groups) and 62 patients who received MEC (30 in the S group and 32 in the R group) were enrolled. One patient from the S group of the HEC study was excluded because of disease progression before the antiemetic treatment; hence, only 57 patients who received HEC were evaluable (**Figures [1](#F1){ref-type="fig"}**, **[2](#F2){ref-type="fig"}**). All patients enrolled in the two phase II studies had a good nutritional status, and had neither muscle wasting nor weight loss. The patients' characteristics are summarized in **Table [1](#T1){ref-type="table"}**. The baseline characteristics of the study subjects were similar between the groups in both the HEC and MEC studies. In the HEC study, the median patient age was 65 years (range 46--76 years), of whom 77.2% were men and most (96.5%) had a good ECOG PS (0--1). The most common histology was adenocarcinoma (54.4%), followed by small cell carcinoma (24.6%), and squamous cell carcinoma (14.0%). Most of the patients (87.7%) were treated with palliative chemotherapy. The combined chemotherapeutic agents with CDDP were as follows: pemetrexed (29.8%), pemetrexed plus bevacizumab (22.8%), etoposide (14.0%), vinorelbine (8.8%), irinotecan (12.3%), gemcitabine (8.8%), docetaxel (1.8%), and S-1 (1.8%). As for the MEC study, the median patient age was 70 years (range 45--89 years); 77.4% were men and most (95.2%) had a good ECOG PS of 0--1. The most common histology was adenocarcinoma (46.8%), followed by squamous cell carcinoma (30.6%) and small cell carcinoma (12.9%). Most of the patients (95.2%) were treated with palliative chemotherapy. The combined chemotherapeutic agents with carboplatin were as follows: pemetrexed (29.0%), nab-paclitaxel (27.4%), etoposide (17.7%), S-1 (9.7%), paclitaxel plus bevacizumab (6.5%), pemetrexed plus bevacizumab (3.2%), gemcitabine (3.2%), paclitaxel (1.6%), and amrubicin (1.6%).

![CONSORT diagram showing patients disposition in the highly emetogenic chemotherapy (HEC) study.](fphar-08-00972-g001){#F1}

![CONSORT diagram showing patients disposition in the moderately emetogenic chemotherapy (MEC) study.](fphar-08-00972-g002){#F2}

###### 

Patient characteristics.

                                            HEC           MEC                         
  ----------------------------------------- ------------- ------------- ------------- -------------
  Age (years)                               65 (46--73)   66 (55--76)   68 (45--79)   71 (49--89)
  Sex                                                                                 
      Male                                  21            23            22            26
      Female                                7             6             8             6
  ECOG performance status                                                             
      0                                     14            17            8             12
      1                                     13            11            20            19
      2                                     1             1             2             1
  Histology                                                                           
      Adenocarcinoma                        18            13            13            16
      Squamous cell carcinoma               3             5             9             10
      Large cell carcinoma                  2             0             1             0
      Not other specified                   0             0             2             0
      Small cell carcinoma                  5             9             5             3
      Large cell neuroendocrine carcinoma   0             1             0             2
      Pleomorphic carcinoma                 0             1             0             1
  Type of chemotherapy                                                                
      Adjuvant                              5             2             0             3
      Palliative                            23            27            30            29
  Dose of cisplatin (mg/m^2^)                                                         
      60                                    2             6                           
      75                                    14            10                          
      80                                    12            13                          
  Dose of carboplatin (AUC)                                                           
      4                                                                 0             2
      5                                                                 20            18
      6                                                                 10            12
  Combined drugs with platinum                                                        
      Pemetrexed                            8             9             9             9
      Pemetrexed + Bevacizumab              8             5             1             1
      Irinotecan                            1             6             0             0
      Docetaxel                             0             1             0             0
      Vinorelbine                           5             0             0             0
      Gemcitabine                           1             4             1             1
      S-1                                   1             0             2             4
      Paclitaxel                            0             0             1             0
      Paclitaxel + Bevacizumab              0             0             2             2
      Nab-paclitaxel                        0             0             7             10
      Amrubicin                             0             0             0             1
      Etoposide                             4             4             7             4
                                                                                      

Efficacy
--------

In the HEC study, the CR rates in the overall phase were 67.9% (95% confidence interval \[CI\], 47.7--84.1) in S group and 62.1% (95% CI, 42.3--79.3) in R group (*P* = 0.65), which did not meet the primary endpoint. In the MEC study, the CR rates in the overall phase were 83.3% (95% CI, 65.3--94.4) in S group and 84.4% (95% CI, 67.2--94.7) in R group (*P* = 0.59), which met the primary endpoint (**Table [2](#T2){ref-type="table"}**). In the HEC and MEC studies, rikkunshito did not exhibit additional improvement on CR rates in the overall phase. Furthermore, rikkunshito did not improve CR rates for the acute and delayed phases in either the HEC or MEC study. Rikkunshito administration also did not improve CP or TC rates in the acute, delayed, or overall phases in the HEC and MEC study. The median dietary intakes were also similar between the S and R groups (89 and 89 mm in the HEC study, and 90 and 91 mm in the MEC study, respectively). Subgroup analyses according to sex, age, alcohol intake, smoking status, ECOG PS, body mass index, motion sickness, dexamethasone dose, treatment line, histology, CDDP, or CBDCA dose, and combined drugs revealed no additional benefit for rikkunshito administration on CR rates in the acute, delayed, or overall phases (data not shown).

###### 

Inter-group comparisons of efficacy outcomes.

                          HEC          MEC                                           
  ----------------------- ------------ ------------ ------ ------------ ------------ ------
  No emesis                                                                          
      Overall             26 (92.9%)   25 (86.2%)   0.41   30 (100%)    28 (90.6%)   0.06
      Acute               28 (100%)    28 (96.6%)   0.51   30 (100%)    32 (100%)    1
      Delayed             26 (92.9%)   25 (86.2%)   0.41   30 (100%)    28 (90.6%)   0.06
  No significant nausea                                                              
      Overall             18 (64.3%)   21 (72.4%)   0.51   24 (80.0%)   24 (75.0%)   0.64
      Acute               28 (100%)    27 (93.1%)   0.25   29 (96.7%)   30 (93.8%)   0.52
      Delayed             18 (64.3%)   21 (72.4%)   0.51   24 (80.0%)   24 (75.0%)   0.64
  No nausea                                                                          
      Overall             16 (57.1%)   16 (55.2%)   0.88   21 (70.0%)   21 (65.6%)   0.71
      Acute               26 (92.9%)   26 (89.7%)   0.52   28 (93.3%)   28 (87.5%)   0.37
      Delayed             16 (57.1%)   16 (55.2%)   0.88   21 (70.0%)   21 (65.6%)   0.71
  Complete response                                                                  
      Overall             19 (67.9%)   18 (62.1%)   0.65   25 (83.3%)   27 (84.4%)   0.59
      Acute               27 (96.4%)   26 (89.7%)   0.32   30 (100%)    32 (100%)    1
      Delayed             19 (67.9%)   18 (62.1%)   0.65   25 (83.3%)   27 (84.4%)   0.59
  Complete protection                                                                
      Overall             17 (60.7%)   18 (62.1%)   0.92   21 (70.0%)   23 (71.9%)   0.87
      Acute               27 (96.4%)   26 (89.7%)   0.32   29 (96.7%)   31 (96.9%)   0.73
      Delayed             17 (60.7%)   18 (62.1%)   0.92   21 (70.0%)   23 (71.9%)   0.87
  Total control                                                                      
      Overall             15 (53.6%)   15 (51.7%)   0.68   20 (66.7%)   20 (62.5%)   0.73
      Acute               26 (92.9%)   25 (86.2%)   0.35   28 (93.3%)   29 (90.6%)   0.53
      Delayed             15 (53.6%)   15 (51.7%)   0.89   20 (66.7%)   20 (62.5%)   0.73
                                                                                     

Safety
------

Rikkunshito was well tolerated, with frequencies of treatment-related adverse events similar to those reported in the S groups. Most adverse events were mild and were associated with the patients' cancer and/or chemotherapy treatment. The most common treatment-related adverse events were constipation, diarrhea, and hiccups. No severe adverse events attributed to antiemetic treatments were reported in either study (**Table [3](#T3){ref-type="table"}**).

###### 

Treatment-related adverse events.

                 HEC study    MEC study                                                              
  -------------- ------------ ----------- ------------ ---------- ----------- ---------- ----------- ---
  Constipation   13 (46.4%)   0           13 (44.8%)   0          6 (20.0%)   1 (3.3%)   5 (15.6%)   0
  Diarrhea       1 (3.6%)     0           4 (13.8%)    1 (3.4%)   4 (13.3%)   0          1 (3.1%)    0
  Hiccups        4 (14.3%)    0           5 (17.2%)    0          0           0          3 (9.4%)    0
                                                                                                     

Discussion
==========

To the best of our knowledge, this study was the first prospective trial designed to evaluate the efficacy and safety of herbal medicine for the prevention of CINV in patients with lung cancer receiving HEC and MEC. Herbal medicines are inexpensive dietary supplements that can boost the body's immune system and have the potential to improve anorexia and CINV in cancer patients. The orexigenic hormone ghrelin is a 28-amino acid peptide and has an *n*-octanoyl modification on Ser3; it was first isolated from rat stomachs and was found to be an endogenous ligand for the receptor of the growth hormone secretagogue. Additionally, ghrelin also has an intense appetite-enhancing effect ([@B15]). A decrease in the concentration of circulating ghrelin along with appetite loss has been observed in CDDP-treated rats ([@B30]). Administration of exogenous ghrelin peripherally improves anorexia ([@B16]; [@B30]) and vomiting ([@B26]) induced by CDDP.

Rikkunshito is an herbal medicine prepared by combining eight herbal medicines: *Atractylodis lanceae rhizoma*, *Ginseng radix*, *Pinelliae tuber*, *Hoelen*, *Zizyphi fructus*, *Aurantii nobilis pericarpium*, *Glycyrrhizae radix*, *and Zingiberis rhizoma* ([@B28]; [@B19]). Rikkunshito stimulates ghrelin secretion from the stomach and the response to it in the hypothalamus ([@B30]; [@B5]). It is widely used in Japan for the treatment of upper gastrointestinal symptoms in patients with functional dyspepsia ([@B3]), gastroesophageal reflux disease ([@B31]), and chemotherapy-induced nausea for cancer patients ([@B32]; [@B23]). Based on these findings, we posited that rikkunshito can improve CINV and conducted this prospective study to evaluate its efficacy for the prevention of CINV in patients with lung cancer who were receiving HEC and MEC.

In the HEC study, the CR rates in the overall phase were 67.9% in the S group and 62.1% in the R group, which did not meet the primary endpoint goals. These results were inferior to previous phase III study results that revealed overall CR rates of 59--77% ([@B10]; [@B24]; [@B17]; [@B29]). On the other hand, the overall phase CR rates in our MEC study were 83.3% in the S group and 84.4% in R the group, which met the primary endpoint goals. These results were superior compared to previous phase III trial results that yielded overall CR rates of 54--74% ([@B7]; [@B1]; [@B25]). Despite having the CINV symptoms, patients enrolled in these two studies were diligent with fulfilling the requirements for daily-recommended nutrients. Therefore, the patients had well to excellent food intake throughout the course of these two studies.

In the present study, rikkunshito was safe and manageable; however, it did not demonstrate any additional benefits beyond those of standard antiemetic regimens used for the prevention of CINV in patients receiving HEC and MEC for lung cancer. Moreover, rikkunshito did not show additional benefits when performing subset analyses of various clinical factors. One possibility that remains to be investigated is that rikkunshito did not sufficiently increase the plasma levels of acylated ghrelin (the active form of ghrelin) in the patients included in this study. For ethical reasons, we did not examine the level of ghrelin in each patient.

The frequency of CINV in patients receiving HEC remained high, which is a challenge that remains to be solved. Olanzapine, which inhibits multiple neurotransmitters, has been reported to produce favorable results and could be an attractive treatment option for CINV prevention ([@B22]; [@B6]). In the present study, olanzapine was not used as part of the standard antiemetic regimen, but it was used as a rescue medication in one patient who was receiving HEC.

Conclusion
==========

Rikkunshito was well tolerated; however, it did not show any additional benefits beyond those of standard antiemetic regimens for the prevention of CINV in patients with lung cancer who were receiving HEC and MEC. Further investigation is required to improve CINV control, especially in patients receiving HEC.
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